Corcept Therapeutics Incorporated. Stock News

Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer Conference Call Participants David Amsellem - Piper Sandler Matt Kaplan - Ladenburg Swayampakula Ramakanth - H. C. Wainwright Joon Lee - Truist Opera...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended September 30, 2024. Financial Results “In the t...

Corcept's upcoming Q4 announcements include pivotal trial results for Relacorilant in ovarian cancer, Dazucorilant in ALS, and an NDA filing for Relacorilant in Cushing's. Positive results from these trials could significantly boost CORT's revenue potential, especially in non-Cushing's applications like cancer and ALS. Corcept's academic alliances enhance its research capabilities, supporting t...

The top five biotech stocks today have several commonalities. Among them are strong ratings.

Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong momentum that could lead to additional upward movement. We follow up on these three small biotech/biopharma names and bring followers up to date on the recent positive news flow around them in the para...

Corcept is a profitable midcap biotechnology company specializing in treating Cushing's Syndrome, with significant potential for revenue growth and expansion into other therapeutic areas. Recent study suggests Cushing's Syndrome is more prevalent than believed, leading to a significant expansion of its potential patient base. Corcept has developed Relacorilant as a far safer and more effective ...

NEW YORK , Aug. 26, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of the company's shareholders.  The investigation seeks to determine whether Corcept's directors breached their fiduciary duties in connection with recent corporate actions.

Corcept Therapeutics' strong Q2 earnings exceed expectations, with revenue climbing 39% YoY and EPS beating analyst estimates. The District Court ruled in favor of Teva, enabling the launch of a generic Korlym, which threatens Corcept's revenue. Corcept faces a lawsuit accusing it of antitrust behavior and alleged illicit bribes.